Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
January 21, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients ...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
January 10, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients Initiating U.S. BLA Submission for...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
November 18, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021
November 08, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
November 04, 2021 07:45 ET | Orchard Therapeutics (Europe) Limited
Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders ...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
October 13, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
September 14, 2021 06:00 ET | Orchard Therapeutics (Europe) Limited
Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
September 09, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021
September 08, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor...